metformin has been researched along with Peutz-Jeghers Syndrome in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Peutz-Jeghers Syndrome: A hereditary disease caused by autosomal dominant mutations involving CHROMOSOME 19. It is characterized by the presence of INTESTINAL POLYPS, consistently in the JEJUNUM, and mucocutaneous pigmentation with MELANIN spots of the lips, buccal MUCOSA, and digits.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carling, D | 1 |
| Foretz, M | 1 |
| Guigas, B | 1 |
| Viollet, B | 1 |
1 review available for metformin and Peutz-Jeghers Syndrome
| Article | Year |
|---|---|
LKB1: a sweet side to Peutz-Jeghers syndrome?
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Gluconeogenesis; Human | 2006 |
1 other study available for metformin and Peutz-Jeghers Syndrome
| Article | Year |
|---|---|
[From cancer to diabetes treatment : the tumor suppressor LKB1 as a new pharmacological target].
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Cyclic AMP Response El | 2006 |